*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). There appears to be no added benefit in the combined use of desmopressin with an AB or an anticholinergic.Several other systematic reviews have been published in this area but with notable differences. 2013 Sep;190(3):965-72. doi: 10.1016/j.juro.2012.12.112. *The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). Epub 2012 Oct 9.Neurourol Urodyn. In all, 11 studies did not meet the inclusion criteria or were not relevant to the question under question Intervention: desmopressin 0.2 mg oral with alfuzosinIntervention: desmopressin 0.1/0.2/0.4 mg oral; dose titrationIntervention: desmopressin nasal spray 0.75, 1.0, or 1.5 μgIntervention: desmopressin 0.2 mg oral + tamsulosinIntervention: desmopressin 10, 25, 50, or 100 μg ODTIntervention: desmopressin 10, 25, 50, or 100 μg ODTThree included studies administered desmopressin as a nasal spray We included five comparisons in this review, of which eight studies compared desmopressin to placebo We included eight studies comparing desmopressin vs placebo with short‐term follow‐up Only one study reported data of duration of first sleep episode for short‐term follow‐up We included one study comparing desmopressin vs AB for all review outcomes in short‐term follow‐up We included three studies comparing desmopressin plus AB vs AB alone with short‐term follow‐up We included one study with short‐term follow‐up in this comparison We did a subgroup analysis on two studies that compared participants with nocturnal polyuria vs without We were unable to conduct subgroup analysis due to a lack of relevant data in the included studies.We were unable to conduct subgroup analysis due to a lack of relevant data in the included studies.We did a subgroup analysis on two studies that compared participants with nocturnal polyuria vs without We were unable to conduct subgroup analysis due to a lack of relevant data in the included studies.We identified published protocols for four included studies and rated the risk of bias as low. *The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). Objectives: To assess the effects of desmopressin as compared to other interventions in the treatment of nocturia in men. For intermediate‐term follow‐up (3–12 months), desmopressin may reduce the number of nocturnal voids in an appreciable number of men (MD −0.85, 95% CI: −1.17 to −0.53; low QoE). The tablet form of desmopressin belongs to the class of medications known as antidiuretics.It is a hormone taken by mouth to control excessive urination during the night (bedwetting).It is also used to treat central diabetes insipidus, a condition where the kidneys are unable to conserve water due to a lack of antidiuretic hormone (ADH). Please enable it to take advantage of the complete set of features! Sand PK, Dmochowski RR, Reddy J, van der Meulen EA.J Urol. N‐QoL, Nocturia Quality of Life Questionnaire. 2013 Apr;32(4):363-70. doi: 10.1002/nau.22306. In a pharmacodynamic study following sublingual administration of 60 mcg desmopressin (1.2 and 2.4 times the maximum recommended dose in men and women, respectively) with suppression of the endogenous vasopressin release by continuous intake of water, the mean time to onset of antidiuretic action was observed within 30 minutes and lasted 6 hours after dosing.